Member Info for Jimzi

Correct, its MTA partner approval i.e they like it. {no nasty FDA!}

Cash Position

Strong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.

Before this statement there was £2.2m rev and costs £3.1m. So its poss the co may become profitable at the end of the year.

Profitable life sciences at EV£3m do not exist - multiple earning valuations kick in so this is not a one rev co

Not your normal spivvy AIMer handing out loads at mates rates prices. Quantity low, price high - as it should be - to align interests.

The Options will vest in three instalments and will have an exercise period of five years. The first tranche

will vest when the closing mid-market share price reaches 7.5 pence or above for three consecutive trading

days. The second tranche will vest when the share price reaches 12.5 pence. The third tranche will vest when

the share price reaches 17.5 pence. .

Thought the tide was turning until the 70k and 250k sell at the close.

Gonna take a bit longer to get sentiment back

Volume is derisory for the drop. IMO there's a few trying to test how far it can drop..

The model is still excellent [ recurring rev and insurer marketing]- smart meters are totally different - so that was just a ruse. Insurance!!. I can only assume it has dropped 50% this year as we haven't has new contracts every month, along with a bit of boredom and a bit of botty wobbling.

£15m written off because they are growing cautiously - GLA

None apart from it being shorted to death on Nas listing because it was a spac listing

Be careful - MDAI moved to nasdaq at 60p, now 17p. Shorts kill smaller tech

$23m for a co with FDA breakthrough tech, no competition, $15b market and $250m gov funding for US rollout.

They did.

Just check Intra’s post about 2 weeks ago instead of trying to read the book on a minute by minute basis. All u need to know

It always trades like this. If there was an overhang, 300k wouldn't be priced at 12.7.

60m shares trade differently but sell up if your worried.

FFS, the 40.5k was a roll/isa.

Stop bloody bickering and post some market research for us.

They already have a strategic investor lined up , who clearly sees value and wants in.

Very rare opp to get in at the very bottom and acquire a couple of % for peanuts to tuck away

Remember, 11p was the placing price in Dec; the placing where they bit the bullet to get 4 years of funding sorted.

Currently an EV of £3.2m - that's an insane value disconnect for rev generating with world's leading tech. Just under the radar atm

Posted April 21

In Intra's excellent post , few have picked up this huge USP, need & urgency - total reliance on Australian and NZ cows.

"One of these has signed an MTA to look at RUA’s new composite material which, based on its own benchtop trials, it claims is considerably stronger, tear resistant yet thinner and flexible, ideal for TAVR and all improvements over current technologies which rely on animal tissue sourced from cows in Australia and New Zealand, the only BSE-free herds in the world. You can see why the majors will eventually want to develop something new that doesn’t rely on a risky supply chain such as these animals. If BSE invaded Australia, these majors would freak out."

The current mcap [ex cash of £4m] is £4m.

They are not just a one trick pony.

- core business growing and revenues expected to double

- heart value being testing with leading partner with plans to commercialise

-VASCULAR GRAFT developed and looking to partner

No placing for years and NO WARRANTS..

60m shares.

If you can't work this one out, give up!

To be fair, GE agreement was late August so won’t have much impact on 2023 figures.

I think the results are in line and it’s still good at controlling the costs.

Agree , good to add quality to the BOD. And balance sheets wise also agree. With last sale instalment and placing, the EV is just £250k - with just 70m shares, easily a parabolic stock if you have a little patience

Very nice having the company underwritten by a strategic investor a] they must see potential b] de-risks the company.

So far impressed with the ambitious yet careful bod.

Indeed, and he wants the sp to languish for a while so that the placing looks justified. Won’t be down forever and at least the biggest hurdle of sp growth for many years has gone - the CLs

Excellent find.